Palliative treatment of bone metastases in hormone-refractory prostate cancer: Effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels

Urologia Internationalis

Volumn 78, Issue 4, 2007, Pages 345-350

  Kawashima, Hidenori ^a   Tanaka, Tomoaki ^a   Kuratsukuri, Katsuyuki ^a   Uchida, Junji ^a   Sugimura, Kazunobu ^a   Tamada, Satoshi ^a   Nishisaka, Nobuyasu ^a   Kumata, Katsuyuki ^a   Iwai, Yoshihito ^a   Ikemoto, Shinichi ^a   Ezaki, Kazuyoshi ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bisphosphonate; Bone metastases; Carboxyterminal telopeptide of type I collagen; Pamidronate; Prostate cancer, hormone refractory

Indexed keywords

BICALUTAMIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CHLORMADINONE ACETATE; DEXAMETHASONE; DIETHYLSTILBESTROL; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GONADORELIN DERIVATIVE; PAMIDRONIC ACID; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD LEVEL; BONE ATROPHY; BONE METABOLISM; BONE METASTASIS; BONE TURNOVER; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 34248165512     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100840     Document Type: Article

References (26)

1. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Fontana D, Angeli A: Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol 2001;166:2023-2031.
2. Saad F, Schulman CC: Role of bisphosphonates in prostate cancer. Eur Urol 2004;45:26-34.
3. Ralston SH: Pathogenesis and management of cancer associated hypercalcemia. Cancer Surv 1994;21:179-196.
4. Kanis JA, McKloskey EV, O'Doherty D: Treatment of Paget's disease with the new bisphosphonates;in Singer FR, Wallach S (eds): Paget's Disease of Bone: Clinical Assessment, Present and Future Therapy. New York, Elsevier, 1991, p 112.
5. Reginster JY, Lecart MP, Deroisy R, et al: Prevention of postmenopausal bone loss by tiludronate. Lancet 1989;2:1469-1471.
6. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic metastases. Protocol 19. Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
7. Cresswell SM, English PJ, Hall RR, Roberts JT, Marsh MM: Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br. J Urol 1995;76:360-365.
8. Adami S: Bisphosphonates in prostate carcinoma. Cancer 1997;80(suppl 8):1674-1679.
9. Heidenreich A, Hofmann R, Engelmann DH: The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001;165:136-140.
10. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
11. Scher HI, Liebertz C, Kelly WK, et al: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997;15:2928-2938.
12. Droz J-P, Kattan J, Bonnay M, Chraibi Y, Bekradda M, Culine S: High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancer. Cancer 1992;71(suppl):1123-1130.
13. Nishimura K, Nonomura N, Yasunaga Y, et al: Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000;89:2570-2576.
14. Urakami S, Igawa M, Kikuno N, et al: Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol 2002;168:2444-2450.
15. Koga H, Naito S, Koto S, et al: Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate 1999;39:1-7.
16. Noguchi M, Noda S: Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 2001;166:1106-1110.
17. Okamura T, Akita H, Tatsura H, Kawai N, Nagata D, Azemoto M, Iwase Y, Kohri K: The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies. Cancer Detect Prev 2003;27:14-18.
18. de la Piedra C, Castro-Errecaborde NA, Traba ML, Mendez-Davila C, Garcia-Moreno C, Rodriguez de Acuna L, Rodriguez-Molina J: Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 2003;331:45-53.
19. Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate ibandronate promote apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-4424.
20. Hiraga T, Ueda A, Tamura D, et al: Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 2003;106:973-979.
21. Diel IJ, Solomayer E-F, Costa SD, et al: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-363.
22. Saarto T, Blomqvist C, Virkkunen P, Elomaa I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001;19:10-17.
23. Lee MV, Fong EM, Singer FR, Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-2608.
24. Boissier S, Ferreras M, Peyruchaud O, et al: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-2954.
25. Fournier P, Boissier S, Filleur S, et al: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-6544.
26. Asahi H, Mizokami A, Maeda Y, Komatsu K, Koshida K, Namiki M: Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J Urol 2003;169:281-282.